Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The study for innovative strategies is warranted in the treatment of advanced non-squamous
NSCLC with epidermal growth factor receptor wild-type or unknown mutation status because the
outcomes remain unsatisfactory for most patients. Maintenance treatment after first-line
chemotherapy is a very interesting strategy that has been largely investigated in the last
years. This study is to evaluate the efficacy and toxicity of thalidomide in combination with
chemotherapy and as maintenance treatment in patients with advanced non-squamous NSCLC.